Vnitr Lek 2025, 71(8):530-534

Mirikizumab in the therapeutic portfolio for inflammatory bowel diseases

Jan ©»ovíček
Interní klinika FN v Motole, Klinika Restrial Praha

Mirikizumab is a newly available biologic that expands the range of targeted therapies for inflammatory bowel disease. As a selective inhibitor of interleukin 23, it demonstrates beneficial effects in patients with ulcerative colitis and Crohn's disease, particularly in those who have not responded to previous treatment. Clinical studies indicate a favorable efficacy and safety profile, supporting its inclusion in current therapeutic strategies. This review summarizes existing knowledge on the mechanism of action, key clinical trial findings, and practical considerations related to the use of mirikizumab in the management of intestinal inflammation.

Keywords: mirikizumab, ulcerative colitis, Crohn's disease, IL-23, biologic therapy.

Accepted: November 26, 2025; Published: December 15, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©»ovíček J. Mirikizumab in the therapeutic portfolio for inflammatory bowel diseases. Vnitr Lek. 2025;71(8):530-534.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Jarkovský J, Beneąová K, Hejduk K, Duąek L, Lukáą M. Epidemiologie, hospitalizační léčba a migrace IBD pacientů za období 2007-2015 v České republice. Gastroenterol Hepatol. 2017;7(6):501509.
    2. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329342. Go to original source...
    3. Oppmann B, et al. Novel IL23 heterodimeric cytokine. Immunity. 2000;13:715725.
    4. Gálvez J. Role of Th17 cells in the pathogenesis of human IBD. ISRN Inflamm. 2014;2014:928461. Go to original source...
    5. Kobayashi T, et al. IL23 differentially regulates the Th1/Th17 balance in UC and CD. Gut. 2008;57(12):16821689. Go to original source...
    6. Friedrich M, et al. IL23 as a target in IBD therapy: current evidence and future perspectives. Int J Mol Sci. 2023;24(6):5426.
    7. Chen L, Ruan G, Cheng Y, Yi A, Chen D, Wei Y. The role of Th17 cells in inflammatory bowel disease and the research progress. Front Immunol [Internet]. 2023 Jan 9 [cited 2025 Sep 10];13:1055914. Available from: https://doi.org/10.3389/fimmu.2022.1055914 Go to original source...
    8. Lochmatter C, Fischer R, Charles PD, et al. Integrative phosphoproteomics links IL23R signaling with metabolic adaptation in lymphocytes. Sci Rep. 2016;6:24491. Go to original source...
    9. Pastras P, Aggeletopoulou I, Papantoniou K, Triantos C. Targeting the IL23 receptor gene: a promising approach in IBD treatment. Int J Mol Sci. 2025;26:4775. Go to original source...
    10. Turner D, et al. STRIDEII: an update on therapeutic goals in IBD. Gastroenterology. 2021;160:14501463. Go to original source...
    11. European Medicines Agency. Omvoh (mirikizumab) - Summary of Product Characteristics [Internet]. EMA; 2025 [cited 2025 Sep 10]. Available from: https://www.ema.europa.eu/en/documents/product-information/omvoh-epar-product-information_en.pdf
    12. Lilly. Mirikizumab Investigator's Brochure. Version 17 [Internet]. 2024 [cited 2025 Sep 10]. Available from: Lilly, data on file.
    13. U.S. Prescribing Information. OMVOH (mirikizumab-mrkz) injection. Eli Lilly and Company; revised 01/2025 [cited 2025 Sep 10]. Available from: https://pi.lilly.com/us/omvoh-uspi.pdf
    14. Friedrich S, Chua L, Adams DH, Crandall W, Zhang XC. Mirikizumab exposure-response relationships in UC. Clin Pharmacol Ther. 2024;116(2):435447. Go to original source...
    15. Chua L, Friedrich S, Zhang XC, et al. Mirikizumab pharmacokinetics in UC: results from LUCENT studies. Clin Pharmacokinet. 2023;62(10):14791491. Go to original source...
    16. Sandborn WJ, et al. Mirikizumab in UC - LUCENT 1 and 2. N Engl J Med. 2023;389:23892401.
    17. Sands BE, et al. TwoYear Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT3 OpenLabel Extension Study. Inflamm Bowel Dis. 2024;30(12):22452258. Go to original source...
    18. Ferrante M, et al. VIVID Study Group. Efficacy and safety of mirikizumab in patients with moderatelytoseverely active Crohn's disease: a phase 3, multicentre, randomised, doubleblind, placebocontrolled and activecontrolled, treatthrough study. Lancet. 2024 Dec 14;404(10470):24232436. Label Extension Study. Inflamm Bowel Dis. 2024 Dec 5;30(12):22452258.
    19. Feagan BG, et al. GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22;369(8):699710. Go to original source...
    20. Vuyyuru SK, Solitano V, Hogan M, MacDonald JK, Zayadi A, Parker CE, Sands BE, Panaccione R, Narula N, Feagan BG, Singh S, Jairath V, Ma C. Efficacy and Safety of IL12/23 and IL23 Inhibitors for Crohn's Disease: Systematic Review and MetaAnalysis. Dig Dis Sci. 2023 Sep;68(9):37023713. Go to original source...
    21. National Institute for Health and Care Excellence. Mirikizumab for treating moderately to severely active Crohn's disease. NICE Technology Appraisal Guidance TA1080 [Internet]. London: NICE; 2025 [cited 2025 Sep 10]. Available from:???
    22. National Institute for Health and Care Excellence. Mirikizumab for treating moderately to severely active Crohn's disease. NICE Technology Appraisal Guidance TA1080 [Internet]. London: NICE; 2025 [cited 2025 Sep 10]. Available from: https://www.nice.org.uk/guidance/ta1080
    23. Travis S, Hisamatsu T, Fischer M, Dubinsky M, Jairath V, Chen M, Ferrante M, Peyrin-Biroulet L, Siegmund B, Gibble T Hunter, Lin Z, Protic M, Morris N, Ghosh S, et al. Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn's Disease: Results from a phase 3 clinical trial. J Crohns Colitis. 2024;18(Suppl_1):i21-i23 (Supplement), January 2024. doi:10.1093/ecco-jcc/jjad212.0012 Go to original source...
    24. Schmitt H, et al. Expansion of IL23 receptor bearing TNFR2+ T cells is associated with molecular resistance to antiTNF therapy in Crohn's disease. Gut. 2019 May;68(5):814828. Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.